Table 3.
Progression-free survival in univariate and multivariate analyses
| Variables | Median (95% CI) | P-value | |
|---|---|---|---|
| Univariate | Multivariate | ||
| Age (years) | 0.037 | 0.089 (HR: 0.46, 95% CI: 0.21–1.12) | |
| ≥65 | 5.3 (3.59–7.01) | ||
| <65 | 3.8 (2.41–5.19) | ||
| Gender | 0.422 | ||
| Female | 4.2 (3.25–5.15) | ||
| Male | 4.6 (3.52–5.68) | ||
| Smoking history | 0.178 | ||
| Smoker | 5 (3.55–6.45) | ||
| Non-smoker | 4 (1.49–6.51) | ||
| ECOG performance status | 0.029 | 0.017 (HR: 2.26, 95% CI: 1.16–4.39) | |
| 0–1 | 5.5 (4.26–6.74) | ||
| ≥2 | 3.6 (2.47–4.73) | ||
| Pathological type | 0.53 | ||
| Adenocarcinoma | 4.2 (3.56–4.84) | ||
| Non-adenocarcinoma | 5 (3.78–6.22) | ||
| Line of apatinib | 0.212 | ||
| Second line | 5.3 (4.34–6.26) | ||
| Further line | 3.6 (3.1–4.1) | ||
| Location | 0.515 | ||
| Central | 4 (2.23–5.77) | ||
| Peripheral | 4.6 (3.76–5.44) | ||
| Apatinib-induced hypertension | 0.0027 | 0.011 (HR: 0.413, 95% CI: 0.21–0.82) | |
| Yes | 5.6 (3.75–6.85) | ||
| No | 4.2 (3.28–5.12) | ||
Abbreviation: ECOG, Eastern Cooperative Oncology Group.